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Abstract 
 
Rheumatoid  arthritis  (RA)  is  one  of  the  most  common  chronic  diseases 
worldwide.  It  is  characterised  by  inflammatory  cell  infiltration  and  bone 
erosion.  Current  therapy  using  non-steroidal  anti-inflammatory  drugs 
(NSAIDs) and glucocorticoids are not very effective and can have severe 
side effects. New generation recombinant drugs while effective are costly. 
Thus, better therapeutic  strategies  are critically needed. Natural  products 
with fewer side effects and which are less expensive may represent ideal 
drugs for clinical RA. Resveratrol is a phytoalexin mainly derived from the 
skin of red grapes. Many in vitro and in vivo studies have demonstrated that 
resveratrol  has  a  wide-range  of  anti-oxidant,  anti-proliferative  and  anti-
inflammatory properties. The aim of this project was to establish whether 
resveratrol  has  an  effect  on  the  development  and  pathogenesis  of 
inflammatory arthritis.   
Collagen induced arthritis (CIA) is a well-studied animal model for human 
rheumatoid arthritis was used here to study the role of resveratrol in RA.  It 
was first determined whether resveratrol could prevent CIA. CIA mice were 
administered with different doses of resveratrol before the onset of arthritis. 
It  was  found  that  20mg/kg  but  not  15  mg/kg  of  resveratrol  reduced  CIA 
clinical parameters and severity of joint histology respectively. Second effect 
of resveratrol on established CIA was investigated and there was evidence 
that  resveratrol,  when  given  after  the  onset  of  CIA,  could  effectively 
suppress the progress and severity of CIA. The clinical anti-arthritic effect of 
resveratrol  was  accompanied  by  the  reduction  of  collagen-specific 
antibodies in CIA mice. Additionally, resveratrol treatment also dramatically 
reduced the levels of inflammatory cytokines, in particular, IL-17, IFN-g and 
TNF-a  in  the  serum.  The  number  of  T  lymphcytes  was  also  reduced,  in 
particular the IL-17 and IFN-g expressing CD4
+T cells in DLN. 
The  results  therefore  demonstrate  that  resveratrol  has  the  property  to 
prevent and treat inflammatory arthritis by modulating the key auto-antigen-
specific antibody and T cell responses. Thus, resveratrol, a natural product 
may have the potential to be used as a novel drug for arthritis.    11 
1. INTRODUCTION 
 
 
1.1 Rheumatoid arthritis 
  
RA,  a  chronic  inflammatory  disease,  is  characterised  by  articular 
redness  and  swelling,  together  with  cartilage  and  bone  destruction, 
although  the  haematological,  cardiovascular  and  respiratory  systems 
are  also  frequently  affected.  This  systemic  autoimmune  disease  is 
induced by a combination of genetic, immune and inflammatory factors. 
RA is a common disease worldwide and is one of the major causes of 
morbidity and premature mortality. 
 
 
1.2 Pathology of rheumatoid arthritis  
 
      1.2.1 Joint pathology 
       The joints most commonly involved in RA are those of the hands 
and  feet,  then  the  elbow,  wrist,  knee,  ankle,  hip  and  spine. 
Hyperplasias of synovial cells occur in the joint, which can form 
villi protruding into the joint cavity. Connective tissue under the 
synovium  is  infiltrated  with  lymphocytes,  macrophages  and 
plasma cells.  Furthermore, endothelial cells highly express inter-
cellular  adhesion  molecule  (ICAM)-1,  and  this  contributes  to 
neovascularity  [1].  Owing  to  this  hyperplasia,  inflammatory 
infiltration  and  neovascularity,  the  synovium  forms  a  pannus, 
which gradually creeps through the whole surface of the cartilage. 
Finally,  the  joint  cavity  will  be  filled  with  fibrotic  and  calcified 
pannus, which leads to permanent ankylosis of the joint.  
   12 
 
 
Figure 1. Histological changes observed in joint of CIA mice. It can be 
seen that compared with the normal joint (A), the joint suffering from 
arthritis  (B)  has  significant  infiltration  of  inflammatory  cells.  Bone 
erosion and hyperplasia are more severe. This figure is reprinted from 
(Utility of animal models for identification of potential therapeutics for 
rheumatoid arthritis) [2] with permission. 
 
       1.2.2 Non joint pathology 
        Because RA is a systemic disease, many organs can be affected.   
25% of patients with RA have subcutaneous nodules. They can 
also have acute necrosis, and when serosa is involved, patients 
will suffer from pleurisy and pericarditis. 
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1.3 Symptoms of rheumatoid arthritis 
 
Epidemiological studies indicate that RA can start at any age. However, 
80% of sufferers who develop RA are initially aged between 35 and 50 
and females are three times more likely than males to experience RA 
[3]. Although RA affects patients differently, for most people, it develops 
slowly  and  gradually.  Before  the  typical  articular  symptoms  appear, 
some  sufferers  can  have  flu-like  symptom  such  as  fever,  as  well  as 
tiredness and weight loss.  
 
1.3.1 Joints 
 
1)  Morning stiffness 
Affected joints feel stiff in the early morning for at least 1 hour 
after first waking up. This is called “morning stiffness” (such 
symptoms  can  also  be  present  in  the  day  time  if  there  has 
been  no  movement  for  a  long  time).  More  then  95%  of  RA 
patients have such symptoms, and there is a positive relation 
between the duration of the stiffness and the severity of the 
disease. 
 
2)  Pain  
Joint  pain  is  the  earliest  symptom.  It  is  systemic  and 
continuous, but the severity fluctuates. Patients with RA in the 
early stages can experience tenderness in their joints while in 
later  stages  sometimes  brown  discolouration  of  the  skin 
occurs.  
 
3)  Swelling of the joint 
Swelling is caused by the excess fluid in the articular cavity 
and  inflammation  of  the  soft  tissue  surrounding  the  joint.  
Furthermore,  the  synovium  thickens  because  of  the 
inflammation.  All  the  affected  joints  can  swell,  but  the  most 
common are the wrists, knuckles and knees. 
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4)  Articular deformity   
Joint deformity is usually present in the last stages of disease 
in long-term RA patients. Swan neck and boutonniere can be 
considered  as  types  of  deformity.  Some  individuals  with 
severe RA lose joint function. 
 
1.3.2 Non joint deformities  
1) Lungs 
It is common for  lungs to  be  affected,  but  this  occurs more 
often in men than in women. Sometimes lung illness can be 
the earliest symptom. Interstitial inflammation  and fibrosis  of 
the  lung  can  present  among  RA  patients,  which  is 
characterized  by  shortness  of  breath  and  impaired  lung 
function.  Pleural effusion is also closely associated with RA. 
 
2) Heart 
  The heart can be affected both in patients with acute and with 
chronic RA, and pericarditis is the commonest type of heart 
disease in these patients.  Additionally, RA can increase the 
risk  of  developing  atherosclerosis,  myocardial  infarction  and 
strokes. 
 
3) Kidneys 
Renal amyloidosis can occur as a consequence of vasculitis. 
 
4) Nervous system 
Peripheral neuropathy can occur due to pressure from swelling 
tissues, and there is a positive relationship between the severity 
of synovitis and neuropathy. Mononeuritis multiplex is caused by 
vasculitis. 
 
5) The blood system 
      Felty’s syndrome can be caused by RA. This is associated with 
an  enlarged  spleen,  decreased  neutrophils  and  platelets,  and   15 
anaemia.  Anaemia  is  commonly  associated  with  chronic 
inflammatory disorders and the severity of the anemia is closely 
related to the progress of rheumatoid arthritis. 
 
 
1.4 Diagnosis of rheumatoid arthritis 
 
The diagnosis of RA is primarily by clinical judgement and this can be 
supported by laboratory adjuncts.    
 
1.4.1 Blood test 
Some  patients  suffer  from  anemia  with  increased  platelets. 
Increased  erythrocyte  sedimentation  rate  (ESR)  and  serum 
concentrations  of  C-reactive  protein  (CRP)  reflect  activity  of  the 
acute phase response and are closely related to the activity of the 
disease. Furthermore, the presence of rheumatoid factors (RF), the 
antoantibody  can  be  indicative  of  RA  although  they  can  be 
transiently increased in a variety of inflammatory diseases. IgM is 
the most common isotype of RF in clinical tests, and is present in 
70% of patients and is associated with the activity and severity of 
RA.  However,  RF  is  not  an  RA  specific  antibody.  Research  has 
indicated that 5% of a sample of the normal population had a low 
level  of  RF  present  [4].  Citrulline  antibody  (also  referred  to  as 
anticitrulline antibody, anti-cyclic citrullinated peptide antibody, and 
anti-CCP) is most useful in investigating the aetiology of previously 
undiagnosed RA when traditional blood test indicates that RF is not 
present.  Another  antibody  called  antinuclear  antibody  (ANA)  is 
frequently found in individuals with RA. 70% of patients tested are 
found  to  have  these  various  immune-complexes  present  in  their 
serum. This is more common in patients who are RF positive or in 
the active stage.  
 
1.4.2 Synovial fluid 
For normal people, the volume of fluid in the synovial cavity is no 
more  than  3.5  ml.  For  individuals  with  RA,  fluid  increases  in  the   16 
inflammatory  joints  with  the  enhanced  level  of  white  cells,  and 
neutrophils are the predominant cell type. 
 
       1.4.3 Imaging  
X-ray is useful to diagnose RA even though there may be no obvious 
changes at the early stage of the disease. However, as the disease 
advances, X-ray can show the bony erosion and subluxation. Apart 
from  X-ray,  other  medical  imaging  techniques  such  as  magnetic 
resonance imaging and ultrasound can also be used to diagnose and 
stage progression of RA. 
 
 
1.5 Diagnostic criteria 
The American College of Rheumatology has defined the following criteria 
for the classification of rheumatoid arthritis (1987): 
 
1) Morning stiffness lasting more than 1 hour most mornings for at least 6 
weeks. 
 
2) Arthritic swelling present for at least 6 weeks in more than 3 out of 14 
joints and soft tissues or joint groups. 
 
3) Arthritis of hand joints, present for at least 6 weeks. 
4) Symmetric arthritis, present for at least 6 weeks. 
5) Subcutaneous nodules present in specific places. 
6) Rheumatoid factor at a level above 95
th percentile. 
7) Radiological changes suggestive of joint erosion 
 
      At least four of the above criteria have to be met for classification as RA 
[5]. 
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1.6 Aetiology and mechanisms 
 
1.6.1 Environmental factors 
 
      So far, no environmental factor has been defined as contributing to 
the  development  of  RA,  however,  some  microorganisms  such  as 
bacteria,  viruses  and  mycoplasmas  can  affect  the  onset  and 
progression  of  RA.  RA  is  more  likely  to  afflict  people  in  western 
countries,  suggesting  that  lifestyle  and  dietary  habits  should  be 
considered  as  factors  contributing  to  the  incidence  of  rheumatic 
disease [6]. Moreover, recent data indicate that smoking and stress 
are also independent risk factors for the incidence of autoimmune 
disease [7, 8].   
 
1.6.2 Genetic factors 
 
Epidemiological studies indicate that there is a positive correlation 
between  genetic  factors  and  the  incidence  of  RA.  12-30%  of 
monozygotic twins will both develop RA, while for fraternal twins it 
is  4%  [9].  International  studies  report  that  HLA-DR4  haploidy  is 
closely  associated  with  the  onset  of  RA.  Hormones  also  play  a 
pivotal  role,  since  epidemiology  indicates  that  females  are  three 
times  more  likely  to  develop  RA  than  males  and  the  disease 
severity fluctuates during the menstrual cycle and pregnancy [10, 
11].  
 
1.6.3 Dysregulation of immunity and inflammation 
 
Immune dysregulation is strongly associated with RA. The inflamed 
joint  tissue  is  characterized  by  the  infiltration  of  lymphocytes 
including activated CD4
+ T lymphocytes and antigen presenting cells 
(APC)  and  the  expression  of  a  spectrum  of  pro-inflammatory 
cytokines,  such  as  TNF-a  and  IL-17  in  the  synovium.  T  cells, 
previously Th1 and now Th17 cells are thought to play a pivotal role 
in the initiation and persistence of inflammatory arthritis [12]. Pro-
inflammatory  cytokines,  in  particularly  TNF-a  are  the  main   18 
pathogenic inducer that drives pathogenesis of RA [13]. It has been 
clinically confirmed that TNF blockage therapy can effectively control 
the  severity  and  development  of  RA  [14].  Activated  T  cells  and 
macrophages  can  produce  cytokines  including  tumour  necrosis 
factor (TNF)-α, interleukin (IL)-1, IL-6 and IL-17, which subsequently 
cause  chronic  inflammation  in  the  synovium  by  different 
mechanisms.  For  instance,  TNF-α  can  degrade  the  articular 
cartilage and bone, by stimulating osteoclast activity, leading to joint 
deformity.  Additionally,  activated  B  lymphcytes  differentiate  into 
plasma  cells,  and  these  release  a  large  amount  of  autoantibody. 
These  include  rheumatoid  factors,  which  may  form  an  immune 
complex with self-antigens and can trigger inflammation through the 
activation of the complement system. The abnormality in the normal 
programmed cell death may be also involved in joint inflammation in 
RA.  The excess Fas molecules, or the disproportion of Fas and Fas 
ligands,  can  interrupt  the  apoptosis  of  synovial  cells.  Thus, 
controlling the key cellular and humoral immune responses and the 
dominant pro-inflammatory cytokine productions may represent the 
possible therapeutic strategies against RA. 
 
 
1.7 Treatment 
      Rheumatoid arthritis is normally treated with NSAIDs, and intra-articular 
therapies (glucocorticoids), which are not curative but merely palliative, 
aimed at reducing symptoms, decreasing disability and enhancing quality 
of  life.  Biological  therapies,  such  as  anti-TNF-a  and  anti-CD20  are 
effective, however, only 30 % of patients can receive these therapies and 
they  are  very  expensive.  This  restricts  their  general  application.  Thus, 
economic drugs with more effciency and less side effects are still needed.  
       1.7.1 Non steriodal anti-inflammatory drugs (NSAIDs) 
       Non-steroidal  anti-inflammatory  drugs  (NSAIDs)  such  as                       
acetylsalicylate  (Aspirin),  naproxen  (Naprosyn),  ibuprofen  (Advil, 
Medipren, Motrin) and etodolac (Lodine) are medications, which can   19 
decrease pain and inflammatory cell infiltration, but do not inhibit the 
progress of RA. 
       1.7.2 Gluco-corticosteroids    
        Along  with  NSAIDs  corticosteroids  are  a  “first  line”  medication. 
Both  are  fast  acting  but  corticosteroids  are  more  potent  than 
NSAIDs  in  reducing  joint  inflammation.  They  can  be  used  for  a 
short period during the acute stage of the disease and the dosage 
depends  on  the  severity  of  RA.  However,  corticosteroids  exert 
many  serious  side  effects,  such  as  weight  gain,  high  risk  of 
infection,  development  of  cataracts  and  thinning  of  the  skin  and 
bone. Also the abrupt withdrawal of corticosteroids can lead to a 
flare-up of the disease.  
        1.7.3 Disease-modifying anti-rheumatic drugs (DMARDs)  
Unlike  NSAIDs  and  corticosteroids,  disease-modifying  anti-                 
rheumatic drugs (DMARDs) are “slowing acting” drugs, which are 
used for a long period of time. Examples of these include cytotoxic 
drugs methotrexate and immuno-suppressive drugs. Sometimes a 
number of DMARDs are used together as combination therapy. 
         1.7.4 Biological therapy 
Compared  with  the  traditional  treatments,  biological  medications 
such  as  anti-TNF-α,  anti-IL-1,  anti-CD20  and  anti-cytotoxic  T 
lymphocyte  activation antigen-4  (CTLA-4) are more directed  and 
targeted.  The  best  example  of  these  is  the  recombinant  human 
soluble  TNF  receptor  (Etanercept  or  Enbrel)  which  has 
demonstrated extensive efficacy and limited side effects. Clinical 
trials indicate that newer drugs have anti-inflammatory effects and 
slow  down  the  progress  of  bone  erosion.  Biological  medications 
used  in  combination  with  traditional  treatments,  such  as 
methotrexate and other DMSRDs can enhance their efficiency and 
reduce the negative side effects they cause.    20 
Although the etiology of rheumatoid arthritis is still unknown, there is an 
increasing recognition among rheumatologists that early diagnosis and 
early medical intervention play a crucial role in improving outcomes. In 
some cases of severe joint deformity, surgery may be necessary.          
 
1.8 Natural properties of resveratrol 
 
      The  natural  function  of  resveratrol  is  to  protect  plants  against  fungal 
infection  (e.g.  Botrytis  cinerea)  [15,  16];  environmental  stress  such  as 
ultraviolet  C  irradiation  [17]  or  heavy  metal  contamination  [18].  These 
factors can increase the production of resveratrol [19].   
 
 
1.9 Chemical and physical properties of resveratrol 
Resveratrol (3, 5, 4'-trihydroxy-stilbene) is a phytoalexin first detected in 
the  roots  of  white  hellebore  in  1940  [20].  There  are  two  geometric 
isomers: cis-(Z) and trans-(T). The “trans” form is more stable than the 
“cis”  form,  which  can  transform  into  the  “trans”  form  when  exposed  to 
ultraviolet irradiation [19]. A high concentration of resveratrol is found in 
the skin of red grapes [21], and it also occurs in cranberries, peanuts and 
pine nuts [22].   
    21 
     
 
     Figure2.  The  structure  and  source  of  resveratrol.  A  simple  structural 
diagram  of  3,5,4'-trihydroxy-trans-stilbene  (resveratrol).  This  is  a 
phytoalexin produced by a variety of plants; some indicated. This figure is 
reprinted  from  Resveratrol  addiction:  To  die  or  not  to  die  [19]  with 
permission.  
 
1.10 Biological effects of resveratrol  
        1.10.1 Anti-inflammatory effects 
Some studies suggest that resveratrol could reduce C5a- induced 
lymphocyte recruitment, free radical formation and the production 
of  cytokines  [23].  Resveratrol  also  reduces  signalling  of  IgE 
receptor ligation, and thus can alleviate inflammatory responses 
by blocking allergen mediated degranulation of mast cells [24]. In 
addition, resveratrol downregulates activation of the transcription 
of  NF-kB,  and  suppresses  LPS-induced  joint  inflammation  and 
bone  erosion  in  rabbit  [25].  For  example,  in  vitro  experiments 
show that resveratrol can decrease TNF-α induced ICAM-1 and 
VCAM-1  expression  in  endothelial  cells  by  regulating  the 
activation  of  NF-kB  [26].  The  reduction  of  IL-4  and  IFN-  γ 
   22 
production  shows  that  resveratrol  can  block  both  Th1  and  Th2 
activation [27, 28]. 
           1.10.2 Cardio protective effects 
Since  the  discovery  of  the  “French  paradox”  (low  incidence  of 
cardiovascular  disease in southern  France, perhaps due to the 
regular  intake  of  red  wine),  resveratrol  has  been  extensively 
researched  and  identified  with  effects  on  the  cardiovascular 
system  [23].  Three  main  effects  have  been  identified:  1) 
resveratrol can decrease the expression of vascular cell adhesion 
molecule (VCAM)-1 [26]; 2) resveratrol can inhibit the proliferation 
of vascular smooth muscle cells [29]; 3) resveratrol can reduce 
platelet aggregation [19]. 
        1.10.3 Anti-cancer effects 
Animal  experiments  have  shown  that  application  of  resveratrol 
can  prevent melanoma developing in mice  treated  with chronic 
UVB exposure [30]. In vitro studies indicate that resveratrol can 
induce apoptosis of cancer cells [31]. Resveratrol can modulate a  
balance    between    cell  death  and  proliferation  and  induce  the 
apoptosis of cells which may contributtte to tumor formation. This 
proporty involve in the regulation of survial and apoptotic factors, 
including Bcl 2 as well as  proteins involved in DNA synthesis, 
such as p53 [32].  
        1.10.4 Anti-aging and anti-diabetic effects 
Investigation  of  resveratrol  indicates  that  it  can  prolong  the 
lifespan  of  yeast  by  stimulating  the  activity  of  Sir2,  which  can 
increase DNA stability and extend lifespan [33] and the fruit fly 
[34]. In an animal experiment, resveratrol was shown to reduce 
the blood sugar level in type 2 diabetes due to the ability to delay 
the onset of insulin resistance [35]. 
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2. Materials and methods 
 
 
2.1 Animals and reagents 
 
      Male DBA/1 mice were obtained from Harlan Laboratories UK. All mice 
were  used  at  9-10  weeks  old  and  maintained  at  the  Joint  Animal 
Facilities,  University  of  Glasgow.  Mice  were  divided  into  three  groups 
(n=10): prevention group, treatment group and control group. All animal 
experiments were performed in accordance with the Home Office, United 
Kingdom, and animal welfare guidelines.  
 
     Bovine Type II Collagen was purchased from MD Biosciences USA, which 
was 2mg/ml in dilute (0.1M) acetic acid. Resveratrol and other chemical 
were  purchased  from  Sigma  Aldrich  (Poole,  U.K.)  unless  otherwise 
stated.  Resveratrol  (>99%  purity)  was  diluted  in  dimethyl  sulphoxide 
(DMSO),  and  the  working  concentration  for  in  vivo  experiments  was 
20mg/kg or 15mg/kg per mouse, respectively. 
 
2.2 Induction of experimental collagen-induced arthritis (CIA)        
      For Collagen-Induced Arthritis (CIA), mice were immunised by intradermal 
injection of 100ul Bovine Type II Collagen emulsified in CFA (Complete 
Freund’s  Adjuvant)  (Difco,  Detroit,  MI,  USA)  at  the  base  of  the  tail 
(Collagen should be emulsified in CFA at 4°C) , 2-3cm from the body on 
day 1. This was followed by a booster of 100ul collagen in IFA (Incomplete 
Freund’s Adjuvant) injected at the base of the tail on day 21.  
 
2.3 Assessment of arthritis 
Mice  were  monitored  daily  for  signs  of  arthritis.  Scores  were  assigned 
based on erythema, swelling, or loss of function present in each paw on a 
scale of 0–3, giving a maximum score of 12 per mouse. Footpad thickness 
was measured with a dial calliper (Kroeplin, Munich, Germany). 
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2.4 Administration of resveratrol 
 Mice received daily i.p. injection of 100ul resveratrol diluted in DMSO. For 
the prevention group, mice received resveratrol each day from day 14 to 
day 21 (onset of arthritis), and the treatment group received resveratrol 
from  day  21  to  day  28.  Control  mice  received  the  equal  volume  of 
resveratrol on day 14 or day 21 accordingly.  
  
2.5 Histological assessment 
Paws were removed and fixed in 10% neutral buffered formalin (NBF). 
For standard heamatoxilin and eosin (H&E) staining, the fixed footpads 
were decalcified in 10% solution of nitric acid in distilled water. This was 
replaced with fresh solution every alternate day until decalcification was 
completed.  After  decalcification,  the  footpads  were  transferred  to  70% 
ethanol  for  paraffin  embedding  and  processing.  5µm  sections  were 
stained with haematoxylin and eosin (Sigma) as described before. 
 
2.6 Measure of cytokines and serum Abs levels 
Blood  samples  were  collected  immediately  after  death  by  retro-orbital 
puncture and serum was separated by centrifugation (1400rpm, 10 mins) 
and stored at -20° C until used. Cytokine concentrat ions including IL-17, 
TNF-α,  IFN-g,  IL-6,  IL-4,  IL-1,  IL-2  and  IL-10  were  determined  by  a 
commercial  20-plex  mouse  cytokine  assay  according  to  the 
manufacturer’s instructions (Invitrogen, UK). Serum total antibody titres in 
pooled sera were detected with biotin-conjugated rat anti-mouse IgG1 or 
IgG2a  (PharMingen,  USA)  followed  by  conjugated  avidin  peroxidase 
(Sigma) and developed with tetramethylbenzidine substrate (Kirkegaard & 
Perry, Gaithersburg, MD, USA). When collagen II-specific antibody was 
measured, the plate was coated with 2mg/ml collagen II first, after adding 
the serum do the same procedure as total antibody. Optical density was 
acquired by ELISA reader at 450 um.  
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2.7 Cell culture in vitro 
On day 29 after primary immunisation, mice were sacrified and the spleen 
and  draining  lymph  nodes  (Axillary,  Epitrochlear  and  Popliteal)  were 
removed. Single-cell suspensions were prepared and were cultured at 2 
×10
6 cells/ml in RPMI 1640 suppled with 100 IU/ml penicillin-streptomycin, 
2mM L-glutamine and 10% FCS (all from Life Technologies, USA) at 37° C 
in 5% CO2 in a 24-well flat-bottom plate (Nunc, Roskilde, Denmark). Cells 
were  stimulated  with  anti-CD3  (2µg/ml),  and  then  were  cultured  in  the 
presence or absence of 30mM of resveratrol based on our pilot result. For 
controls, cells were stimulated without anti-CD3 and resveratrol. 72 hours 
later, supernatants were collected and concentrations of IL-17, IFN-g, GM-
CSF, MIP-1α, IL-1β, TNF-α, IL-13, IL-5, IL-12, IL-4, IL-10 and IL-2 were 
determined by luminex. 
 
2.8 Flow cytometry 
DLN  cells  (1×10
6)  were  stained  with  FITC,  PE  or  APC  conjugated 
antibodies  for  CD4,  IL-17  and  IFN-g  with  appropriate  isotype-matched 
control (BD). All samples were pre-incubated with CD16/32 to block FcR. 
Then cells were analysed on FACS Calibur flow cytometry (BD). All results 
represented on individual mice (n=5).  
 
2.9 Statistics 
To determine the significance distribution of the clinical scores, we analysed 
the statistical differences between the resveratrol treated and control DBA 
mice models. Clinical scores, collagen-specific IgG levels were compared 
with a Student’s t test for unpaired observation (Mann-Whitney was used as 
well, got the similar result). Mann-Whitney U tests were used for histological 
scores  by  SPSS  software.  P  values  less  than  0.05  were  considered 
significant. 
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3. Results 
 
 
3.1 Resveratrol prevents the progression of inflammatory arthritis  
 
In  order  to  investigated  whether  resveratrol  could  prevent  the 
development  of  collagen-induced  arthritis  (CIA),  this  was  induced  in 
DBA1  mice  (n=10;  as  described  in  M&M)  and  different  doses  of 
resveratrol  (REV)  dissolved  in  DMSO  or  DMSO  vehicle  control  were 
given by intra-peritoneal injection daily from day 14 for 6 days; all before 
the onset of arthritis typically at day 21. 
 
Two  doses  of  REV  were  tested  (15mg/kg  and  20mg/kg)  in  order  to 
determine its dose effects on CIA. Meanwhile, the control mice received 
an equivalent volume of vehicle DMSO. Mice were monitored daily for the 
development of typical CIA from day 21. 
 
3.1.1 15mg/kg resveratrol does not prevent clinical CIA 
          The mice that received 15mg/kg/dose of REV appeared to have no 
difference  in  disease  incidence  (Fig.  1A),  number  of  diseased 
footpads (1B), footpad thickness (1C) and clinical score (1D) up to 
day 36 compared with those in DMSO controls.  
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 Fig. 1                                            
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Fig.1. 15mg/kg resveratrol does not prevent clinical CIA. The CIA mice were 
treated with 15mg/kg of REV and the clinical parameters of arthritis in CIA 
mice were evaluated including incidence (A), number of diseased footpads 
(B), footpad thickness (C) and clinical index (D). Data were means ± SEM  
 
 
 
   28 
3.1.2 20mg/kg/dose of resveratrol impairs development of CIA 
       However, in the mice that received REV (20mg/kg), the incidence of 
CIA  (Fig.  2A),  the  number  of  diseased  footpads  (2B),  the  footpad 
thickness  (2C)  and  clinical  score  (2D)  were  attenuated  compared 
with the controls on days 37 and 38. Thus, 20mg/kg but not 15mg/kg 
of REV have a preventative effect on the development and severity of 
CIA. 
 
The  histology  of  paws  obtained  from  REV  injected  (20mg/kg)  and 
DMSO  control  CIA  mice  was  further  examined.  It  was  found  that 
resveratrol treatment markedly reduced inflammatory cell infiltration 
and  cartilage  and  bone  erosion.  This  was  further  confirmed  by 
significantly  reduced  histological  score  of  hyperplasia,  erosion  and 
inflammatory cell infiltration in the REV-administered group compared 
with that in DMSO controls (2E). These observations agreed with the 
clinical parameters (Fig. 2A-D) and provide histological evidence that 
resveratrol at 20mg/kg has a preventative effect on the development 
and pathogenesis of CIA. 
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Fig. 2 
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Fig.2. 20mg/kg/dose of resveratrol impairs development of CIA. 20mg/kg REV 
given  prophylactically  attenuated  experimental  CIA.  (A-D)  The  clinical 
parameters  of  arthritis  in  CIA  mice  were  evaluated  including  incidence, 
number of diseased footpads, footpad thickness and clinical index. Data were 
means ± SEM (*, p< 0.05; REV vs. DMSO mice by Student’s t test, n=9). (E) 
Footpads  were  processed for  histology  (M&M).  4  um  tissues  were stained 
with H&E. Histology was analysed by scoring. Original magnification was ´40. 
Data are mean ± SD (*, p< 0.001 compared with DMSO controls by Mann-
Whitney U test).  
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3.2 Resveratrol exerts therapeutic effects on established collagen-   
      induced arthritis 
To  further  determine  whether resveratrol  (20mg/kg) can treat collagen-
induced arthritis, CIA mice were treated with i.p. injection of resveratrol 
and DMSO control after the onset of arthritis on day 23, daily, for 6 days.  
 
Control  mice  that  received  DMSO  vehicle  all  developed  typical  severe 
arthritis by day 28 (Fig. 3A-D). In contrast, compared to the control mice, 
there  was  a  significant  time-dependent  disease  remission  in  the  mice 
after REV treatment. This was evidenced by the impaired incidence (Fig. 
3A), number of diseased footpads (3B), increased footpad thickness (3C) 
and  overall  clinical  index  (3D).  Of  potential  clinical  importance  is  that 
after, 6 days of treatment with REV was sufficient to sustain the reduction 
of clinical parameters of CIA on days 33 and 36 (Fig. 3). 
       
       These  clinical  observations  were  subsequently  confirmed  by  the 
histological examination  of the paws  of CIA  mice. Paws  obtained from 
control  mice  demonstrated  typical  CIA  tissue  pathological  changes, 
enhanced  inflammatory  cell  infiltrations  in  the  joint,  bone  erosions  and 
hyperplasia  (Fig.  3E)  However,  histological  changes  and  pathology 
scores  were  significantly  reduced  in  REV  treatment  mice  compared  to 
those in the controls (3E).  
 
 
       
 
 
 
 
 
 
 
 
   32 
Fig. 3  
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Fig.3.  Resveratrol  treats  established  CIA.  (A-D)  Mice  were  treated  with 
resveratrol  (20mg/kg)  or  DMSO  on  day  23  and  monitored  for  disease 
progress,  including  incidence,  number  of  diseased  footpads,  footpad 
thickness and clinical index. Data were means ± SEM (*, p< 0.05; **, p< 
0.01). (E) Paws were collected for H&E staining and histology score.  
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3.3 Resveratrol reduces the production of collagen specific antibodies       
      in vivo 
Part  of  the  inflammatory  response  associated  with  the  induction  of 
experimental  arthritis  is  the  production  of  antibodies  against  collagen 
antigen. In order to investigate whether the REV-mediated prevention and 
treatment effect on CIA involves the modulation of antibody responses, 
the  total  and  collagen-specific  levels  of  serum  IgG1  and  IgG2a  were 
quantified by enzyme immunoassay (ELISA). 
 
The  collagen-specific  IgG  (IgG1  and  IgG2a)  levels  were  detected. 
Compared  with  the  control  mice,  mice  that  received  20mg/kg  of 
resveratrol  before  the  development  of  arthritis  produced  less  collagen-
specific  IgG2a  and  IgG1  (Fig.  4A).  Similarly,  20mg/kg  resveratrol  also 
significantly  decreased  both  collagen-specific  IgG2a  and  IgG1  levels 
when administered after the development of CIA in mice (Fig. 4B). The 
disease severity seemed to change in parallel with the antibody levels in 
CIA mice. 
 
Despite  these  changes  in  specific  antibody  activity,  there  was  no 
difference in the serum concentrations of total serum IgG2a and IgG1 at 
day  36  between  the  resveratrol-treated  and  the  control  CIA  mice  (Fig. 
4C). 
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Fig. 4 
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Fig.4. Resveratrol reduces collagen specific antibodies in CIA mice. (A-B) 
Anti-collagen IgG2a and IgG1 in mice serum were measured by sandwich 
ELISA. (C) Total IgG2a and IgG1 in the mice serum was determined by 
direct ELISA. Data were mean ± SD (*, p< 0.05; **, p < 0.01 compared 
with DMSO control by Student’s t test).   
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3.4 Resveratrol inhibits inflammatory cytokine production in CIA mice 
 
3.4.1  Preventative  resveratrol  selectively  decreases  the  production  of 
cytokines in CIA mice 
 
          Pro-inflammatory cytokines, including IL-17, TNF-a, IFN-g and IL-6 
play  a  critical  role  in  the  pathogenesis  of  RA  and  CIA.  After  72 
hours culture, we next investigated the role of REV in the regulation 
of inflammatory cytokine production in CIA mice (see M&M). Mice 
that  received  20mg/kg  resveratrol  before  the  development  of 
arthritis produced reduced levels of serum IFN-g, TNF-a, IL-6, IL-4 
and  IL-1  compared  to  those  in  control  mice  (Fig.  5A).  More 
importantly,  a  high-dose  of  REV-treatment  almost  completely 
abrogated IL-17 production in the serum, whereas a lower dose of 
REV failed to do so (data not shown).  
 
          However, REV at the concentration of 20mg/kg did not reduce the 
production  of  inhibitory  cytokine  IL-10  and  the  T-cell  activation 
cytokine  IL-2  (5B),  suggesting  that  resveratrol  selectively  inhibits 
cytokine releases in CIA mice. These data are consistent with our 
observation  that  a  higher  but  not  a  lower  dose  of  resveratrol 
effectively prevents the development of CIA.  
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Fig. 5 
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Fig.  5  Preventative  resveratrol  selectively  decreases  the  production  of 
cytokines in CIA mice. CIA mice were injected with REV on day 14 and 
sacrificed on day 38.  Serum cytokine concentrations were analysed by 
luminex (A, B). Data  were means ± SD (n=10.  *, p< 0.05;  **, p < 0.01 
compared with DMSO control by Student’s t test).   
.  
 
3.4.2  Resveratrol  selectively  decreases  the  production  of  inflammatory 
cytokines in DLN cells in vitro 
 
          Furthermore,  to  confirm  the  inhibitory  effect  of  resveratrol  on 
activated  draining  lymph  node  (DLN)  cells,  we  cultured  the  cells 
with  resveratrol in vitro. Based  on  our pilot experiment,  30µM  of 
resveratrol was selected (data not shown). We found that resvertrol 
completely inhibited IL-17, IFN-g, GM-CSF, MIP-1, IL-1, TNFa, IL-5 
and  IL-13  production  in  cell  culture  supernatant  from  both 
resveratrol-treated and untreated mice. However, it had no effect 
on the production of IL-12, IL-4, IL-2 and IL-10 in the same culture 
supernatant (Fig. 6B), suggesting again, that resveratrol selectively 
suppresses cytokine production. 
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Fig. 6 
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Fig.6.  Resveratrol selectively  decreases the production  of inflammatory 
cytokines in DLN cells in vitro. (A) REV given in vivo and in vitro inhibited 
inflammatory  cytokine  production.  (B)  REV  had  no  effect  on  the 
production of IL-2, IL-4 IL-10 and IL-12 in the culture.  
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3.4.3 Resveratrol can decrease the T cell numbers and the production of 
inflammatory cytokines in CD4
+ T cells 
 
          To  investigate  whether  resveratrol  can  inhibit  CD4
+  T-cell 
proliferation and production of their key cytokines, IL-17 and IFN-g 
in CIA mice, we collected DLN cells from resveratrol-treated and 
untreated mice.  
 
          The size of the draining lymph nodes of CIA mice, which had been 
given  resveratrol  was  notably  smaller  than  the  control  CIA  mice 
(data not shown). The total numbers of lymphocytes collected from 
REV-treated  mice  were  also  significantly  reduced  compared  with 
those in control mice (Fig. 6A). 
 
          We  next  determined  the  number  of  CD4
+  T  cells  in  these  mice. 
Compared to the controls, the absolute numbers of CD4
+ cells were 
markedly reduced in the CIA mice treated with resveratrol (Fig. 6B).  
 
          We cultured the DLN cells with collagen antigens for 72 hours and 
the  intracellular  IL-17  and  IFN-g  levels  in  CD4
+  T  cells  were 
determined by flow cytometry. Compared to the controls, the CD4
+ 
T  cells  from  resveratrol-injected  mice  dramatically  reduced  IL-17 
and IFN-g expression in both total and single cell levels (Fig. 6C). 
The  result  suggests  that  resveratrol  can  also  suppress  the 
important arthritic Th1 cell subset function in CIA mice. 
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Fig. 7 
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Fig.7. Resveratrol can decrease the T cell numbers and the production of 
inflammatory  cytokines  in  CD4
+  T  cells.  (A)  The  total  number  of 
lymphcytes in REV and DMSO mice. (B) The absolute number of CD4
+ T 
cells in the DLN. (C) The IL-17
+ and IFN-g
+ CD4
+ T cells in DLN by FACS.  
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4. Discussion 
 
 
 
4.1 How does REV suppress arthritic response in CIA? 
 
Although the aetiology of RA is still unclear, B cells, T cells, macrophages 
and  synoviocytes  are  closely  involved  in  the  pathogenesis  of  joint 
inflammation  and bone  erosion. The selective depletion of B cells  with 
rituximab can relieve the symptoms in RA patients [36], which indicates 
that B cells contribute to RA [37]. This is probably because B cells can 
produce auto-antibodies and can also act as antigen presenting cells to 
promote arthritis-associated T-cell activation [37]. It has been shown that 
resveratrol can suppress LPS-stimulated B cell proliferation and IgG1 and 
IgG2a production in a dose-dependent fashion [38], and down-regulates 
the expression of CD80, a co-stimulatory molecular for T cell activation 
[38]. Our results also show in vivo that resveratrol inhibits the collagen-
specific IgG production but not total IgG, suggesting that resveratrol may 
mainly  target  ongoing  B  cell  response  but  has  little  influence  on  the 
general B cell homeostasis and function.  
 
RA  was  previously  thought  to  be  a  Th1-cell  associated  inflammatory 
disease; however, increasing evidence has demonstrated that Th17 cells 
play a pivotal role in RA. IL-17, a Th17-derived pro-inflammatory cytokine 
is highly expressed in the synovium and synovial fluid of RA patients. A 
significant suppression of the development of inflammatory arthritis was 
observed in IL-17
-/- mice [39], and the severity of CIA can be inhibited by 
neutralising anti-IL17 antibodies. IL-1 is a critical arthritic cytokine in RA. It 
was suggested that IL-17 might contribute to the synovial inflammation 
and joint destruction in an IL-1-independent manner [40]. In our study, 
resveratrol can significantly inhibit the production of IL-17 in the serum 
and cell culture of CIA mice, suggesting that REV has a profound effect 
on IL-17 production. However, the underlying mechanism is still unknown.  
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The  aryl  hydrocarbon  receptor  (AhR)  is  a  ligand-activated  transcription 
factor that can mediate anti-inflammatory effect [41].  It is reported that 
AhR is required for Th17 development and resveratrol is an inhibitor of 
AhR [42, 43]. This may provide a possible mechanism and explanation for 
how resveratrol inhibits Th17 development in CIA. However, a direct link 
of AhR in resveratrol-inhibited Th17 function and CIA pathogenesis needs 
to  be  confirmed.  Furthermore,  other  cells  can  also  express  IL-17,  for 
instance  monocytes  and  mast  cells.  It  is  currently  unknown  whether 
resveratrol  suppresses  the  cytokine  production  in  different  cells  by 
common or different mechanisms. 
 
Dendritic cells (DCs) represent the most effective antigen-presenting cells 
in the initiation of antigen-specific T and B cell activation [44, 45]. It has 
been reported that resveratrol can induce a dose-dependent reduction in 
the proliferation of T-cell by suppressing DC maturation and function [46]. 
Therefore it is possible that resveratrol may produce such a wide-effect 
on both T and B cell responses by affecting DC functions. This hypothesis 
also needs to be further investigated. 
 
IL-10 is a powerful immune inhibitory cytokine and resveratrol suppressor 
function may be indirect via IL-10. It has been shown that DCs treated 
with  resveratrol  completely  inhibit  IL-12  release  and  increase  IL-10 
secretion [47]. However, there is no difference in the production of IL-12 
and IL-10 in the serum or cultured DLNs with or without resveratrol in our 
CIA context. This suggests that resveratrol suppress other cells but not 
via IL-10 induction.  
 
Additionally, inflamed synoviocytes contribute to the pathology of arthritis, 
and  resveratrol  can  directly  suppress  synoviocytes  proliferation  by 
inducing cell apoptosis via activating caspase-3 [48].   
 
Nevertheless,  resveratrol  can  suppress  ongoing  even  established 
inflammatory  arthritic  response  in  vivo.  The  detailed  mechanism 
underlying the suppression will be investigated in the future.    47 
4.2 The effect of REV in immunity and CIA 
 
Different dose of resveratrol may have opposite effect on immunity. The 
previous in vitro study has shown that resveratrol can modulate B cell 
proliferation and antibody production [49]. At a concentration of 5µmol/L 
resveratrol increased the percentage of CD19
+ B lymphocytes, however, 
10µmol/L resveratrol inhibited proliferation of B cells [49]. Another study 
also  confirmed  the  dose-dependent  effect  of  resveratrol.  As  observed, 
when cultured with resveratrol (10
−8–10
−5 M), the growth of human bone 
marrow-derived  mesenchymal  stem  cell  was  increased,  whereas  REV 
(10
−4 M)  possessed  a  suppressive  effect  on  cell  proliferation  [50].  Our 
results  demonstrated  that  20mg/kg  (0.02M)  dose,  but  not  a  15mg/kg 
(0.015M) dose of resveratrol has preventative and therapeutic effects in 
CIA.  This  higher  dose  of  REV  can  significantly  reduce  antibody 
production while a marginally lower dose REV can only slightly inhibit the 
production of collagen specific antibodies (data not shown). In addition to 
the  antibody  synthesis,  the  reduction  of  pro-inflammatory  cytokine 
secretions in the 15mg/kg resveratrol treated group was less pronounced 
than that in the  20mg/kg group  (data not shown). Histological analysis 
also  confirms  that  a  low  dose  of  resveratrol  has  not  effect  on  the 
prevention of joint inflammation and bone erosion.  
 
Thus,  the  dose  of  resveratrol  should  be  carefully  considered  when 
designing  an  experiment  or  in  the  future  clinical  application  using  this 
natural product. 
 
 
4.3 Potential role of resveratrol in clinical application in RA 
 
     The first line drugs for RA treatment such as NSAIDs and glucocorticoids 
exert effects by non-specifically suppressing the inflammatory response. 
These drugs also have unpleasant side effects. TNF blockers are, the new 
generation drugs that are more effective than NSAIDs in the relief of the 
progress of RA, however, only 40% of subjects respond to the anti-TNF   48 
treatment.  In  addition,  it  is  very  costly  which  may  prevent  its  general 
applications. Over all, current therapies for RA cannot cure the disease 
but  merely  aim  to  reduce  the  symptoms  and  provide  patients  an 
acceptable  quality  of  life.    Thus,  more  effective,  affordable  drugs  with 
minimal side effects are still needed to control this common disorder, and 
natural  products  with  anti-inflammatory  properties  may  be  good 
candidates for this. 
 
The pharmacology and toxicology of resveratrol have been demonstrated 
in  rodents  and  in  man  [51,  52].  The  absorption  and  metabolism  of 
resveratrol  have  been  investigated.  Resveratrol  is  well  absorbed  and 
distributed to all the organs in the human body [53]. No detectable toxic 
effect was observed in rabbits and rats treated with low and high doses of 
high-purity  resveratrol,  up  to  750mg/kg  per  day  for  3  months  [51]. 
Application to human beings has already indicated that there are no, or 
only minor, adverse effects in healthy volunteers even with a high dose of 
resveratrol [52]. Furthermore, resveratrol is commercially available as a 
daily  healthcare  product  to  maintain  general  wellbeing  and  health. 
Therefore the natural product resveratrol may represent a promising drug 
for RA.  
 
 
4.4 Other potential natural products against RA 
     Apart from resveratrol, several other components extracted from plants 
also  display  anti-inflammatory  properties  and  may  have  therapeutic 
potential against RA. Both in vitro and vivo evidence show that curcumin, 
the  polyphenol that  has been  used  as an ingredient in Indian  food for 
centuries, may have potential activity against arthritis. It has been shown 
that curcumin inhibits synoviocyte proliferation and neutrophil activation 
[54].  Other  investigation  suggested  that  curcumin  prevents  joint 
inflammation before but not after the onset of arthritis [55]. Preclinical and 
clinical study shown that guggulsterone, a sterol extracted from gum resin 
can  reduce  pain  and  stiffness  of  the  knee  in  osteoarthritis  [56].   49 
Withanolides, which are derived from withania somnifera can also inhibit 
experimental arthritis [57]. These agents have the common feature that   
they can all suppress the activation of the key transcript factor NF-kB in 
inflammatory response, leading to reduction of a cyclooxygenase (COX-
2) expression [58-60]. Furthermore, several other compounds including 6-
shogalo (a ginger rhizome extract), avemar (a component of the wheat 
germ) [61, 62], avocado and soybeans also exhibit different anti-arthritic 
properties [63]. In summary, we should like to propose that these natural 
products may represent potential valuable drugs for arthritic disorders.  
 
 
Table 1 
Molecular targets of natural products that exhibit anti-arthritic potential 
Compounds              Source                                                  Molecular targets                               Reference 
Boswellic acid           Boswillia serrata (Salai guggul)            NF-kB, COX-2, 5-LOX, MMP-9         [64, 65] 
Berberine                  Berberis bulgaris (barberry)                  NF-KB, COX-2, TNF-a, IL-1b           [66] 
Cekastrol                  Tripterygium wilfordii                             NF-KB, COX-2, MMP-9, TNF-a        [67, 68] 
Curcumin                  Curcuma longaa (tumeric)                    NF-KB, COX-2, 5-LOX, TNF-a 
Eugenol                    Syzygium aromaticum (cloves)             NF-KB, COX-2, 5-LOX, TNF-a          [69] 
Guggulsterone          Commiphora mukul (guggul)                 NF-KB, COX-2, MMP-9                    [56, 59]          
Statins                       Aspergillus terreus (yeast)                    NF-KB, COX-2, MMP-9                    [70, 71]                 
Tea polyphenols       Camellia sinensis (black tea)                 NF-KB, COX-2, 5-LOX, TNF-a         [72]    
Ursolic acid               Ocimum sanctum (holy basil)                NF-KB, COX-2, MMP-9                    [73, 74] 
Withanolides             Withania somnifera (Ashwagendha)      NF-KB, COX-2, MMP-9, ICAM-1      [60, 75] 
 
 
4.5 Future directions 
  In  conclusion,  our  present  study  demonstrated  that  resveratrol  could 
prevent  and  treat  CIA  by  inhibiting  collagen  specific  lymphocyte 
proliferation,  autoimmune  antibody  production  and  pro-inflammatory 
cytokine synthesis, especially IL-17. Further studies should be focused on 
the molecular mechanisms underlying resveratrol’s action, in particularly 
its role in the regulation of the key arthritic B and T cell activities in vitro 
and  in  vivo.  The  longer-term  effect  of  resveratrol  in  treatment  and   50 
prevention  of  RA  also  needs  to  be  assessed  and  compared  with  anti-
TNF-a therapy in the next study in vivo.  Since REV has already been 
applied to human beings and has shown no obvious side effects, it will be 
possible to test its role in RA in the near future. These studies will further 
enhance  our  understanding  of  pharmacological  role  of  resveratrol  and 
establish its potential beneficial effect on RA. 
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